Patents by Inventor Mark Harvey Wilcox

Mark Harvey Wilcox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of inhibiting by administration of oritavancin
    Patent number: 9220749
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: December 29, 2015
    Assignee: THE MEDICINES COMPANY
    Inventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
  • METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN
    Publication number: 20140100157
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Application
    Filed: December 10, 2013
    Publication date: April 10, 2014
    Applicant: THE MEDICINES COMPANY
    Inventors: Mark Harvey WILCOX, Simon BAINES, Dario LEHOUX, Thomas R. PARR
  • Method of inhibiting clostridium difficile by administration of oritavancin
    Patent number: 8629100
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: January 14, 2014
    Assignee: The Medicines Company
    Inventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
  • METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN
    Publication number: 20130310308
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Applicant: The Medicines Company
    Inventors: Mark Harvey WILCOX, Simon BAINES, Dario LEHOUX, Thomas R. PARR
  • Method of inhibiting clostridium difficile by administration of oritavancin
    Patent number: 8518873
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: August 27, 2013
    Assignee: The Medicines Company
    Inventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
  • METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN
    Publication number: 20100311646
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
    Type: Application
    Filed: September 11, 2008
    Publication date: December 9, 2010
    Applicant: TARGANTA THERAPEUTICS CORP.
    Inventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr